XJPX
6190
Market cap9mUSD
May 23, Last price
371.00JPY
1D
-2.88%
1Q
-39.28%
Jan 2017
-80.47%
IPO
-85.89%
Name
PhoenixBio Co Ltd
Chart & Performance
P/E
51.11
P/S
0.79
EPS
7.26
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
6.85%
Revenues
1.72b
-19.24%
Net income
26m
-94.65%
CFO
-79m
L
Profile
PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 1,715,321 -19.24% | 2,124,051 60.33% | |||
Cost of revenue | 1,675,051 | 876,676 | |||
Unusual Expense (Income) | |||||
NOPBT | 40,270 | 1,247,375 | |||
NOPBT Margin | 2.35% | 58.73% | |||
Operating Taxes | 33,407 | 17,314 | |||
Tax Rate | 82.96% | 1.39% | |||
NOPAT | 6,863 | 1,230,061 | |||
Net income | 26,378 -94.65% | 493,329 -227.16% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 37,797 | 142,931 | |||
BB yield | -2.07% | -6.84% | |||
| Debt | |||||
Debt current | 231,588 | 915,257 | |||
Long-term debt | 735,280 | 469,683 | |||
Deferred revenue | |||||
Other long-term liabilities | 3,343 | 3,339 | |||
Net debt | (427,514) | (296,463) | |||
| Cash flow | |||||
Cash from operating activities | (79,307) | 277,491 | |||
CAPEX | (38,773) | (12,368) | |||
Cash from investing activities | 115,358 | (156,340) | |||
Cash from financing activities | (244,879) | 86,630 | |||
FCF | (192,904) | 856,311 | |||
| Balance | |||||
Cash | 1,385,107 | 1,555,323 | |||
Long term investments | 9,275 | 126,080 | |||
Excess cash | 1,308,616 | 1,575,200 | |||
Stockholders' equity | 1,014,942 | 843,462 | |||
Invested Capital | 1,508,947 | 1,741,287 | |||
ROIC | 0.42% | 73.63% | |||
ROCE | 1.59% | 48.26% | |||
| EV | |||||
Common stock shares outstanding | 3,782 | 3,397 | |||
Price | 482.00 -21.63% | 615.00 17.37% | |||
Market cap | 1,822,808 -12.75% | 2,089,082 20.74% | |||
EV | 1,395,294 | 1,794,619 | |||
EBITDA | 65,495 | 1,271,075 | |||
EV/EBITDA | 21.30 | 1.41 | |||
Interest | 2,927 | 3,072 | |||
Interest/NOPBT | 7.27% | 0.25% | |||